1757 related articles for article (PubMed ID: 33988036)
1. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
2. Osimertinib for
Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
4. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
5. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
7. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM
PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
9. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.
Chiang CL; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH
Target Oncol; 2020 Aug; 15(4):503-512. PubMed ID: 32696212
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
11. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
Nakashima K; Ozawa Y; Daga H; Imai H; Tamiya M; Tokito T; Kawamura T; Akamatsu H; Tsuboguchi Y; Takahashi T; Yamamoto N; Mori K; Murakami H
Invest New Drugs; 2020 Dec; 38(6):1854-1861. PubMed ID: 32424780
[TBL] [Abstract][Full Text] [Related]
13. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
[TBL] [Abstract][Full Text] [Related]
14. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K
Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198
[TBL] [Abstract][Full Text] [Related]
15. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
16. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
Wang S; Yan B; Zhang Y; Xu J; Qiao R; Dong Y; Zhang B; Zhao Y; Zhang L; Qian J; Lu J; Zhao R; Han B
Int J Cancer; 2019 Jun; 144(11):2880-2886. PubMed ID: 30474188
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M; Terrasa J; Garrido P; Campelo RG; Aparisi F; Diz P; Aguiar D; García-Giron C; Hidalgo J; Aguado C; González JG; Esteban E; Gómez-Aldavarí L; Moran T; Juan O; Chara LE; Marti JL; Castro RL; Ortega AL; Moreno EM; Coves J; Sánchez Peña AM; Bosch-Barrera J; Gastaldo AS; Núñez NF; Del Barco E; Cobo M; Isla D; Majem M; Navarro F; Calvo V
BMC Cancer; 2021 Mar; 21(1):230. PubMed ID: 33676426
[TBL] [Abstract][Full Text] [Related]
19. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.
Auliac JB; Saboundji K; Andre M; Madelaine J; Quere G; Masson P; Vergnenegre A; Lamy R; Raymond S; Chiappa AM; Hauss PA; Fournel P; Corre R; Chouaid C
Target Oncol; 2019 Jun; 14(3):307-314. PubMed ID: 31119481
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
